Columbia Scientists have joined a consortium to develop new antivirals for SARS-CoV-2 and emerging viruses. 🦠💥🤝 The new consortium is called the Metropolitan AntiViral Drug Accelerator (MAVDA), and it is funded by a five-year, $108 million grant from the Antiviral Drug Discovery Centers for Pathogens of Pandemic Concern program of the National Institutes of Health. A principal member of the new consortium is Professor of Medicine David Ho, who says that, “by combining academia’s expertise in identifying new drug targets and developing promising drug compounds with the pharmaceutical industry’s ability to optimize and test new therapeutics, we can bridge the gaps that often hinder drug development.” The consortium’s overall goal is to quickly develop oral antiviral drugs that patients can take at home, drugs that can combat many different viruses in one package. Full Article Link in Bio📍 #columbiaengineering #biomedicalengineering @columbia_bme #SARSCoV2 #pandemic #newviruses #MAVDA #DavidHo #newgrant